- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:41 | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 14:18 | Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial | 4 | Investing.com | ||
| 14:06 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center | 88 | GlobeNewswire (Europe) | Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European... ► Artikel lesen | |
| 05.05. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer | 414 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.04. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 315 | GlobeNewswire (Europe) | Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting... ► Artikel lesen | |
| 24.03. | Silexion receives Israeli approval for pancreatic cancer trial | 1 | Investing.com | ||
| 23.03. | Silexion Therapeutics: Aktionäre lehnen Kapitalerhöhung und Ausweitung des Aktienplans ab | 2 | Investing.com Deutsch | ||
| 23.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Silexion Therapeutics reports Q4 results | 1 | Seeking Alpha | ||
| 17.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 368 | GlobeNewswire (Europe) | Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer... ► Artikel lesen | |
| 17.03. | Silexion Therapeutics Corp - 10-K, Annual Report | 4 | SEC Filings | ||
| 19.02. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.02. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit | 2 | GlobeNewswire (USA) | ||
| 06.01. | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | 363 | GlobeNewswire (Europe) | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen | |
| 06.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | -1,50 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| AMGEN | 285,00 | -0,51 % | Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks | ||
| NOVAVAX | 8,070 | -1,59 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 170,84 | +0,57 % | Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD | WESTON (dpa-AFX) - Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,000 | +1,12 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,120 | +1,68 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| TEMPUS AI | 39,530 | -1,15 % | Tempus AI nach erneutem Kursrückgang: Risiko-Chance-Profil spitzt sich nach Q1-Zahlen weiter zu | Tempus AI hat nach den Q1-Zahlen erneut einen Kursrückgang verzeichnet, der nach Einschätzung eines Beitrags auf Seeking Alpha ein attraktives Chance-Risiko-Profil für risikobereite Anleger eröffnen... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,910 | +5,47 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,000 | -0,09 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| SAREPTA THERAPEUTICS | 16,520 | +1,35 % | Sarepta tumbles as its gene therapy sales decline further | ||
| EXELIXIS | 43,145 | +2,37 % | TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,124 | +2,70 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| CARDIOL THERAPEUTICS | 1,152 | -0,35 % | Cardiol Therapeutics Inc: Cardiol to publish phase II Maveric results in JAHA | ||
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| ATAIBECKLEY | 3,600 | +2,27 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,013 (-2,16 %) liegt der Kurs bei 0,567 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.